Franklin Resources Inc. reduced its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 228,328 shares of the life sciences company's stock after selling 13,179 shares during the quarter. Franklin Resources Inc. owned about 0.14% of Illumina worth $30,511,000 as of its most recent filing with the SEC.
A number of other institutional investors have also made changes to their positions in the business. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the 4th quarter worth approximately $32,000. Versant Capital Management Inc grew its holdings in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $45,000. Assetmark Inc. lifted its stake in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Illumina during the 4th quarter worth approximately $48,000. 89.42% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
ILMN has been the topic of several analyst reports. HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price on the stock. in a research note on Friday, February 28th. Piper Sandler increased their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Morgan Stanley dropped their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. Finally, Citigroup lowered their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $138.70.
Check Out Our Latest Stock Report on Illumina
Illumina Stock Performance
ILMN traded down $6.21 during trading on Thursday, hitting $70.09. 676,143 shares of the company traded hands, compared to its average volume of 2,247,546. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock's fifty day moving average is $90.77 and its 200 day moving average is $123.08. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The firm has a market cap of $11.10 billion, a P/E ratio of -9.15, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
